Abbott India Q4 Revenue Grows 6.5%, But Net Profit Misses Expectations

Overview

JPMorgan Chase released a report analyzing Abbott India's Q4 financial performance. The report indicates that Abbott India reported Q4 revenue of 17 billion INR, a 6.5% year-over-year increase, but net profit missed expectations primarily due to higher costs and increased taxes.

Core views

Abbott India's Q4 revenue grew 6.5% year-over-year, slightly exceeding analyst expectations, yet net profit fell short. While some key therapeutic areas such as gastroenterology, hormones, and vaccines performed strongly, overall revenue growth remained below market expectations. Sales of insulin brands saw a significant decline, particularly the MIXTARD brand, which dropped 38% year-over-year. Additionally, subpar performance of certain major insulin brands weighed on overall results. Although new products like GLP-1 therapies showed strong performance, overall growth remains constrained.

Analysis framework

The report evaluates Abbott India's market position in key therapeutic areas and the competitiveness of its product portfolio through an analysis of Q4 financial data and sales performance. It also focuses on major challenges faced by the company, including limited new product launches and declining sales of key insulin brands. Analysts assessed the company's short-term and long-term growth prospects by comparing historical data with market expectations.

Key data

• Revenue17 billion INRUp 6.5% year-over-year
• Adjusted EBITDA4.6 billion INRUp 8% year-over-year
• Net ProfitBelow expectationsImpacted by rising costs and increased taxes

Impact & implications

The report concludes that Abbott India currently faces significant challenges, including limited new product launches and declining sales of key insulin brands. Although the company demonstrates strong performance in certain key therapeutic areas, overall growth remains constrained. The neutral rating is maintained with a target price of 27,500.00 INR.